Skip to main content
SpringerLink
Log in

Kommentar zu: Andexanet alfa als Antidot bei schwerwiegenden Blutungen unter Faktor Xa-Inhibitoren

Comment on: Andexanet alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

  • Journal Club
  • Published:
Der Anaesthesist Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Hunt BJ, Levi M (2016) Engineering reversal – finding an antidote for direct oral anticoagulants. N Engl J Med 375:1185–1186

    Article  PubMed  Google Scholar 

  2. Siegal DM, Curnutte JT, Connolly SJ et al (2015) Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 373:2413–2424

    Article  CAS  PubMed  Google Scholar 

  3. Pollack CV Jr., Reilly PA, Eikelboom J et al (2015) Idarucizumab for Dabigatran reversal. N Engl J Med 373:511–520

    Article  CAS  PubMed  Google Scholar 

  4. Grottke O, Frietsch T, Maas M, Lier H, Rossaint R (2013) German Society of Anaesthesiology and Intensive Care Medicine. Dealing with massive bleeding and associated perioperative coagulopathy: recommendations for action of the German Society of Anaesthesiology and Intensive Care Medicine. Anaesthesist 62:213–224

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Köln (AöR), Köln, Deutschland

    H. Lier

  2. Klinik für Anästhesiologie, Experimentelle Hämostaseologie, Universitätsklinikum RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland

    O. Grottke

Authors
  1. H. Lier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Grottke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to O. Grottke.

Ethics declarations

Interessenkonflikt

H. Lier erhielt Vortragshonorare und Reisekostenerstattungen von Bayer Vital, Blutspendedienst West (DRK), CSL Behring, Ferring, Mitsubishi Pharma, Novo Nordisk, Tem International. O. Grottke erhielt Studienförderung von Bayer Healthcare, Boehringer Ingelheim, Biotest, CSL Behring, Novo Nordisk, Nycomed und Portola sowie Vortragshonorare für wissenschaftliche Referate bzw. Beratertätigkeiten von CSL Behring, Boehringer Ingelheim, Bayer, Baxalta, Pfizer, Portola, Octapharma und Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lier, H., Grottke, O. Kommentar zu: Andexanet alfa als Antidot bei schwerwiegenden Blutungen unter Faktor Xa-Inhibitoren. Anaesthesist 65, 940–942 (2016). https://doi.org/10.1007/s00101-016-0240-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00101-016-0240-x

Search

Navigation